Scientists have developed Escherichia coli, which produces psilocybin

A group of scientists from the University of Miami managed to develop a method for producing psilocybin using bacteria. According to experts, microorganisms produce a substance much faster than fungi and require less area.

Psilocybin production technology on an industrial scale

University staff led by Professor Andrew Jones isolated the nucleotide sequence in the fungal DNA chain responsible for psilocybin synthesis. Then the engineers introduced the fungal genome into the DNA of Escherichia coli, which then began to produce psilocybin, fulfilling the established genetic program.

The second phase of the project was to make the bacterium produce psychedelics in large numbers. To solve this problem, experts conducted experiments for several months and achieved high results. Initially, a 1-liter bacterial colony synthesized several milligrams of psilocybin. Subsequently, this figure increased to 1.16 grams. According to Jones, the productivity of microorganisms has grown 500 times.

Unfortunately, the free version of the research report does not indicate the period for which bacteria produce psilocybin. However, Jones is confident that the technology can be used to produce psychedelics on an industrial scale, as its results are superior to all other methods from an economic point of view.

Psilocybin needed for clinical trials

The authors of the research project noted the medicinal potential of psilocybin, which was confirmed by testing the effectiveness of the substance for the treatment of addiction, depression and post-traumatic stress disorder. However, the US authorities do not recognize the healing properties of mushrooms, so they are in Schedule I of narcotic substances.

Despite officials’ skepticism of psilocybin, several American educational institutions have applied for the study of psychedelics. Among them was the Heffter Research Institute, which set two main tasks for scientists:

  1. learn how psilocybin affects the brain and psyche;
  2. develop ways to alleviate side effects from taking the substance.

Institute President George Greer said that experts plan to evaluate the effectiveness of psilocybin in the fight against various types of addiction and mental disorders caused by cancer. One of the most promising areas is considered psilocybin therapy of cancer patients. Nevertheless, doctors say that psychedelics should be consumed only under the supervision of professionals, as it can cause negative consequences: high blood pressure and arrhythmia. In addition, psilocybin can provoke an attack on people who suffer from psychosis or manic disorders.

Canada legalized food and beauty products with cannabinoids

On October 17, Canada entered into force on the legalization of food and beauty products with cannabinoids. Within 60 days, the Ministry of Health will consider applications from companies for the sale of hemp products, so the goods will not appear on store shelves until mid-December.

Cannabinoid products must meet quality standards

Over 40 hemp enterprises informed the Ministry of Health of their plans to begin production of new goods. Agency representatives will examine each product and its packaging for compliance with legal requirements. In this way, authorities will guarantee product safety. All products will be divided into three categories:

  1. Food;
  2. concentrates;
  3. cosmetics.

Vaporizers and cartridges with cannabinoids

Large companies are going to release electronic cigarettes, cartridges with hemp oil and liquids with cannabinoids. Despite the outbreak of the US vaper epidemic, experts predict an increased demand for these types of products. Health officials said Americans caught a respiratory illness by steaming hemp oil with health-hazardous supplements bought on the black market. Officials will ensure that legitimate products do not contain toxic substances, so the use of products from licensed dealers will not lead to negative consequences.

Aphria analysts have compiled a report that states that:

  • vaporizers will account for 20% to 30% of the market;
  • marijuana trade will amount to 60% of the total turnover;
  • cosmetics and food will bring from 10% to 20% of the income.

Aphria, Aurora Cannabis, Organigram Holdings, and Supreme Cannabis have partnered with Pax Labs, a company that produces vaporizers under the Pax Era brand. Cartridges for devices will be purchased from Organigram.

Hemp drinks

Canopy will become a leader in the cannabinoid beverage market as it collaborates with Constellation Brands, the third-largest beer producer in the world. Constellation has invested $ 5 billion in a joint project with Canopy, involving the construction of a factory in Smiths Falls. The facility will produce more than 10 types of alcoholic and non-alcoholic drinks with cannabinoids. Canopy Vice President Jordan Sinclair said his firm has managed to reduce the onset of drug intoxication from hemp drinks from two hours to several minutes.

Organigram is about to sell a tasteless powder with cannabinoids that can be dissolved in liquids. The effect of hemp “Invite” will be noticeable 10-15 minutes after consumption. Hexo, together with brewing company Molson Coors, will launch a line of drinks under the Truss brand.

Cannabinoid Sweets

The former Hershey factory, which is now owned by Canopy Growth, will again start producing chocolate, but with the addition of substances contained in cannabis. To implement the project for the production of sweets, Canopy signed a contract with the leading Canadian chocolatier, Hummingbird. The press service of the enterprise said that the plant will begin to work immediately after it receives permission from the Ministry of Health. Aurora Cannabis plans to produce candy, chewing gum and cookies with cannabinoids.

Hemp sweets should not attract children, therefore it is forbidden to place pictures with cartoon characters on packages, use bright wrappers, and the product in shape should not resemble similar products without the addition of cannabinoids. In addition, the content of THC in sweets cannot exceed 10 mg. This requirement is designed to reduce the chance of an overdose of the substance. In the United States, this dose of cannabinoid is considered standard, however, the Ministry of Health advises starting with 2.5 mg and gradually increasing the dosage, because THC affects people in different ways.